Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Extend Biosciences General Information
Extend Biosciences has developed the proprietary D-VITylation® platform that attaches a vitamin D-based molecule to peptides/proteins, significantly improving their pharmacokinetics by reversible binding to serum vitamin D-binding protein. Their lead candidate, EXT608 for hypoparathyroidism, aims for once-weekly self-administration. Another program, EXT418 for cachexia and peripheral neuropathy, has completed efficacy studies and is IND-ready
Contact Information
Drug Pipeline
No pipeline data available
Key Partnerships
Extend Biosciences Funding
No funding data available
To view Extend Biosciences's complete valuation and funding history, request access »